ScripBloom Science, Inc. is advancing a pipeline of live biotherapeutics derived from gut commensal microbes to alter key brain-gut microbiome interactions in a bid to treat rare neurological disorders. T
ScripBionomics Limited has been all-in on its allosteric ion channel modulator BNC210 in neuropsychiatric indications for years and is bullish about moving forward now that the drug met the primary endpoi
Pink SheetVistaGen Therapeutics, Inc. suffered a significant setback last year when its lead drug candidate fasedienol (PH94B) for treatment of social anxiety disorder failed to meet the primary endpoint in th
ScripVistaGen Therapeutics, Inc. has rebounded from clinical development setbacks before, but investors imposed a severe penalty on the South San Francisco biotech on 22 July following its pre-market anno